Pharmacologic intervention Neurotoxic agent Reference Duloxetine Taxane or platinum Smith et al. (2013a) Gabapentin Vinca or platinum or taxane Rao et al. (2007) Lamotrigine Vinca or platinum or taxane Rao…
Fig. 7.1 Possible management algorithm from Niravath (2013) In large adjuvant trials involving AIs, the incidence of musculoskeletal disorders was reported in 19–35 % of patients on AI’s and 12–29…
Fig. 11.1 Relationships between comorbidities, breast cancer treatment and breast cancer outcomes. Comorbid conditions among breast cancer survivors can negatively influence breast cancer treatment and patient quality of life, increasing…
© Breast Cancer Research Foundation 2015Patricia A. Ganz (ed.)Improving Outcomes for Breast Cancer SurvivorsAdvances in Experimental Medicine and Biology86210.1007/978-3-319-16366-6_1 1. Breast Cancer Survivorship: Where Are We Today? Patricia A. Ganz1 and Pamela J. Goodwin2 (1) UCLA Schools of…
Fig. 10.1 Factors affecting breast cancer prognosis. (a) Characteristics of the tumor will affect likelihood of recurrence and metastasis, and will also determine treatments to be given. (b) The effects…
Etiology Prevention Early detection Follow-up Treatment Survivorship • Biology and • Chemo-prevention • Mammography • Access • Adjuvant chemotherapy • Treatment side effects • Risk factors • MRI • Quality…
Treatment factors Patient factors Disease-related factors Sentinel node biopsy Older age Worse pathologic nodal status Axillary lymph node dissection Obesity and/or high BMI Worse T stage Post-operative axillary radiation History…
